Reference Detail

Ref Type
PMID
Authors Toan Pham, Shienny Sampurno, Lloyd Pereira, Sara Roth, Vignesh Narasimhan, Sandra Carpinteri, Alexander Heriot, Jayesh Desai, Robert G.Ramsay
Title Cancer Vaccine Targeting MYB in Colorectal Cancer: From Pre-Clinical Model to Clinical Trial
Journal Gastroenterology
Vol
Issue
Date
URL https://www.sciencedirect.com/science/article/pii/S0016508518341593
Abstract Text Gastroenterology Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
TetMYB MYB vaccine TetMYB is a DNA vaccine comprised of a modified full-length MYB coding region linked to tetanus peptides, which results in enhanced immune response to MYB expressing tumor cells (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269, PMID: 25671128).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
APC mutant colon adenoma predicted - sensitive TetMYB Preclinical Actionable In a preclinical study, TetMYB treatment resulted in improved median survival compared to control (356 vs 183 days) in APC-driven mouse models of colon adenoma (Gastroenterology, Volume 154, Issue 6, Supplement 1, May 2018, Pages S-1269). detail...